F.D.A. Grants Emergency Authorization of Antibody Treatment Given to Trump
Source: New York Times
The Food and Drug Administration has granted emergency authorization for the experimental antibody treatment given to President Trump shortly after he was diagnosed with Covid-19, giving doctors another option to treat Covid-19 patients as cases across the country continue to rise.
The treatment, made by the biotech company Regeneron, is a cocktail of two powerful antibodies that have shown promise in early studies at keeping the infection in check, reducing medical visits in patients who get the drug early in the course of their disease. A similar treatment, made by Eli Lilly, was given emergency approval earlier this month.
The emergency authorization for Regenerons drug is limited in scope: It is for people who have tested positive for the coronavirus and who are at high risk for developing severe Covid-19. Evidence so far suggests that antibody treatments work best early in the course of the disease, before the virus has gained a foothold in the body. Like Eli Lillys treatment, Regenerons is not authorized for use in people who are hospitalized or who need oxygen.
The emergency authorization raises immediate questions about who will get access to the treatments as an average of more than 168,000 people are diagnosed each day with Covid-19 in the United States and hospitals are running out of beds in some regions of the country. Regeneron has said it will have enough of the drug for only about 80,000 people by the end of November, enough for 200,000 patients by the first week of January, and 300,000 by the end of January. After that, the company said it will be able to ramp up production thanks to a partnership with the Swiss manufacturer Roche.
Read more: https://www.nytimes.com/2020/11/21/health/regeneron-covid-antibodies-trump.html
soothsayer
(38,601 posts)SunSeeker
(51,550 posts)The rest of us are on our own.
RandySF
(58,772 posts)SunSeeker
(51,550 posts)captain queeg
(10,171 posts)BumRushDaShow
(128,858 posts)I think I read that it was some obscene price per treatment.
Newest Reality
(12,712 posts)I think availability will be the issue more than price. It is estimated that Regeneron will cost between $1,200 to $1,500 a dose.
So, who gets it when the supply is limited is the main factor. Jr. probably will.
BumRushDaShow
(128,858 posts)the availability would always be a given and an issue (and I expect the patent was already filed some time ago, so no "generics" any time soon, although you often have companies already working on one anyway ).
mpcamb
(2,870 posts)"...the government has bought 300,000 doses each from Lilly and Regeneron at a cost of about $1,250 and $1,500 p, respectively, with an option to buy hundreds of thousands more."
WaPo article
https://www.washingtonpost.com/health/2020/11/21/regeneron-fda-clearance/